Recipharm has announced the acquisition of GenIbet, a Portuguese CDMO, specializing in the manufacture of biological clinical trial material and novel modalities such as viral vectors, RNA and microbiome.
The acquisition forms part of Recipharm’s strategy to grow in the biologics market, with a